恒瑞医药：维鲁胺片二代AR抑制剂获临床试验批准，研发投入累计6.93亿元

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of Rivoceranib tablets, a second-generation AR inhibitor, which is expected to enhance treatment options for prostate cancer patients [1] Group 1: Product Development - Rivoceranib tablets are a second-generation AR inhibitor that offers stronger AR inhibition without agonistic effects compared to first-generation inhibitors [1] - The drug was approved for market launch in 2022 for treating high tumor burden metastatic hormone-sensitive prostate cancer patients [1] Group 2: Market Potential - According to EvaluatePharma, the global sales of similar products are projected to reach approximately $11.037 billion in 2024 [1] - The company has invested around 693 million yuan in the research and development of this drug [1] Group 3: Regulatory Process - Following the approval of the clinical trial notification, the drug must undergo clinical trials and receive further review and approval from the National Medical Products Administration before it can be manufactured and marketed [1] - The drug development and market launch process involves uncertainties [1]